Forman Stephen J. 4
4 · LIXTE BIOTECHNOLOGY HOLDINGS, INC. · Filed Jul 2, 2021
Insider Transaction Report
Form 4
Forman Stephen J.
Director
Transactions
- Award
Options to Purchase Common Stock
2021-06-30+100,000→ 100,000 totalExercise: $3.03From: 2021-06-30Exp: 2026-06-30→ Common (100,000 underlying)
Holdings
- 8,333
Options to Purchase Common Stock
Exercise: $0.90From: 2017-10-16Exp: 2022-10-16→ Common (8,333 underlying) - 21,053(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $5.70From: 2018-12-07Exp: 2022-12-07→ Common (21,053 underlying) - 8,333
Options to Purchase Common Stock
Exercise: $6.60From: 2019-05-22Exp: 2024-05-22→ Common (8,333 underlying) - 50,000
Options to Purchase Common Stock
Exercise: $3.21From: 2021-01-06Exp: 2026-01-06→ Common (50,000 underlying) - 33,333
Options to Purchase Common Stock
Exercise: $0.96From: 2016-05-13Exp: 2021-05-13→ Common (33,333 underlying) - 16,667(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $6.00From: 2018-12-07Exp: 2022-12-07→ Common (16,667 underlying)
Footnotes (1)
- [F1]Effective June 30, 2021, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting in eight equal installments on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 20, 2021).